Illumina stock rises 2.52% and outperforms competitors

9 articles · Updated · MarketWatch · May 6

Shares closed at $142.58 on Wednesday as the S&P 500 gained 1.46% to 7,365.12 and the Dow rose 1.24% to 49,910.59.
Illumina beat peers including Labcorp, down 0.08%, Charles River Laboratories, down 1.97%, and Quest Diagnostics, down 0.90%.
The stock finished 8.33% below its 52-week high of $155.53 reached on 22 January, while trading volume of 1.3 million stayed below its 50-day average.

Is Illumina's stock surge a sign of a real turnaround, or is the genomics giant about to lose its crown?

Beyond a strong quarter, can Illumina's acquisitions defend its dominance against the rapid rise of new sequencing rivals?